Bo'ai xinkaiyuan Pharmaceutical Co., Ltd. (300109)

Bo'ai xinkaiyuan Pharmaceutical Co., Ltd. (300109)

Boai NKY medical Holdings Ltd. (hereinafter referred to as NKY), stock code: 300109. The company mainly engaged in the production of PVP series products, PVM / MA copolymer and oral care products; Medical technology services such as early tumor screening, molecular diagnosis and individualized precision medicine based on gene sequencing. At present, xinkaiyuan's subsidiaries include Boai xinkaiyuan (Beijing) Medical Technology Development Co., Ltd., Tianjin Boai xinkaiyuan International Trade Co., Ltd., Tianjin arizi Pharmaceutical Technology Co., Ltd., Boai xinkaiyuan pharmaceutical and Chemical Equipment Co., Ltd., Wuhan Haer Medical Technology Development Co., Ltd., Changsha Sanji Biotechnology Co., Ltd Jingneng Biotechnology (Shanghai) Co., Ltd., overseas subsidiary: Germany Boai NKY Chemical Co., Ltd., overseas joint venture: Japan contract new open source Pharmaceutical Co., Ltd.

Xinkaiyuan is a high-tech enterprise which researches, develops and produces PVP series products in China. In the past 30 years, great progress has been made in improving production technology and automatic control level, improving industrial chain structure, expanding production scale and improving quality management level, which plays an important role in the global PVP industry pattern.

In April 2013, a new modern factory covering 208 mu (138800m2) and a total construction area of 50000m2 was completed, which realized the integrated production process of PVP and PVM / MA functional polymer product series. The main devices include: 12000 T / a GBL device, 6000 T / a 2-pyrrolidone device, 6000 T / A NVP device, 2500 t / a PVM / MA COPOLYMER device 2000 t / a vinyl ether plant and 10000 t / a PvP polymer plant. At present, the product series include: GBL, 2-pyrrolidone, NVP monomer, PVP K series (povidone), copurvidone, PVPP (cross-linked povidone), PVP-I complex (povidone iodine), vinyl ether intermediate and PVM / MA copolymer. Xinkaiyuan is also the first domestic enterprise capable of producing PVP K12 (powder and liquid), PVP K90 (povidone K90) powder, PVP K60 powder, k120 powder, PVM / MA copolymer and high purity vinyl ether intermediate.

All pharmaceutical / cosmetic / food / oral care products of the new factory have fully realized cGMP production standards, and become a model of product safety in China's pharmaceutical excipients industry.

Xinkaiyuan has always been committed to process innovation and new product development, and has successively established the company's technology research and development center and Tianjin Polymer Application Research Institute, so as to track the world's technology trends and effectively serve the needs of customers. The company's independent research and development of a number of achievements to fill the domestic gap, has obtained 16 invention patents and 21 utility model patent authorization; 20 computer software copyright certificates have been obtained; We have independently developed 16 proprietary technologies, many of which have reached the domestic or international advanced level; So far, it has obtained 33 trademark registrations.

In recent years, xinkaiyuan has been recognized as a national high-tech enterprise, a key high-tech enterprise under the national Torch Program, and a technology R & D center as a provincial enterprise technology center. It has won many honors such as provincial and municipal advanced enterprises in technology innovation and advanced units in environmental protection work.

The company has obtained the formal registration of EU reach for polymer PVP / monomer NVP (1000 tons / year), registration number 01-2119498301-39-0002.

As a fine chemical enterprise, xinkaiyuan prospectively put forward the dual platform strategy of "consumer characteristic chemicals + health care service" in 2014, and completed the construction of "health care service platform" and xinkaiyuan medical service in 2015.

At present, xinkaiyuan has three subsidiaries in the medical field, namely, Wuhan Haer, Changsha Sanji and Shanghai Jingneng. Meanwhile, xinkaiyuan is acquiring several domestic and foreign medical companies, whose business mainly involves women's health (diagnosis and treatment of cervical cancer and breast cancer) and precision medicine (molecular diagnosis and genetic testing). Xinkaiyuan medical is well aware that the promotion of medical technology depends on strong academic support. In view of this, the company has established a comprehensive and in-depth cooperation with Fudan University, Wuhan University, Central South University and other domestic top universities, as well as Karolinska College of Sweden (Nobel Prize in physiology or medicine), European Society of oncology and other international top universities and institutions.

Xinkaiyuan has reached a cooperation agreement with China Women's development foundation to jointly carry out a series of health public welfare activities for rural women.

Xinkaiyuan is based on the production of health care products and precision medical services. With the concept of fraternity, xinkaiyuan studies the quality of technology, serves the general public and creates a better life.

>> oil pump jack for sale electrical submersible pump manufacturers